|
Mar. 27, 2024 |
|
|
Mar. 27, 2024 |
|
|
jRCT1030230738 |
Association between exercise skeletal muscle oxygen consumption and sarcopenia complications in patients with chronic heart failure |
|
Association between exercise skeletal muscle oxygen consumption and sarcopenia complications in patients with chronic heart failure |
Taiki Yamasaki |
||
Department of Rehabilitation Medicine, Kawasaki Municipal Tama Hospital, Kawasaki, Japan |
||
Kawasaki manicipal hospital 1-30-37 Shukugawara Tama-ku, Kawasaki-shi, Kanagawa-ken |
||
+81-44-933-8111 |
||
herrhiro@marianna-u.ac.jp |
||
Yamasaki Taiki |
||
Department of Rehabilitation Medicine, Kawasaki Municipal Tama Hospital, Kawasaki, Japan |
||
Kawasaki manicipal hospital 1-30-37 Shukugawara Tama-ku, Kawasaki-shi, Kanagawa-ken |
||
+81-44-933-8111 |
||
taiki.yamasaki@marianna-u.ac.jp |
Pending |
Mar. 27, 2024 |
||
| 108 | ||
Interventional |
||
non-randomized controlled trial |
||
open(masking not used) |
||
uncontrolled control |
||
parallel assignment |
||
other |
||
Male heart failure patients aged 40 years or older with a diagnosis of heart failure and scheduled to undergo cardiopulmonary exercise testing as an outpatient at Kawasaki City Tama Hospital will be included. Diagnostic criteria for heart failure will be in accordance with the diagnostic criteria for patients with chronic heart failure in the Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure (2017 revised edition). The severity of heart failure will be defined as stage C (symptomatic heart failure) according to the AHA/ACC (American Heart Association / American College of Cardiology) stage classification. |
||
The following are contraindications to the exercise stress test as outlined by the American College of Sports Medicine. These are: critical myocardial ischemia or acute myocardial infarction (within 2 days of onset), recent nonsignificant resting ECG changes suggestive of other acute cardiac events, unstable angina, symptomatic or poorly controlled arrhythmia resulting in hemodynamic abnormalities, symptomatic severe aortic stenosis, poorly controlled symptomatic heart failure, acute pulmonary embolism or pulmonary infarction, acute myocarditis or pericarditis, dissecting aortic aneurysm or suspected aortic aneurysm, acute pulmonary embolism, or pulmonary infarction. Symptomatic severe aortic valve stenosis, uncontrolled symptomatic heart failure, acute pulmonary embolism or infarction, acute myocarditis or pericarditis, dissecting aortic aneurysm or suspected aortic aneurysm, acute infection with fever, body pain, or lymph gland swelling, or any physical impairment that would interfere with safety or adequate performance of the test. |
||
| 40age old over | ||
| No limit | ||
Male |
||
Heart failure |
||
Measurement of Muscle oxygen saturation during cardiopulmonary exercise testing. |
||
D006333 |
||
Lower extremity muscle oxygen utilization capacity (lower extremity muscle oxygen saturation, arterial-mixed venous oxygen difference) during cardiopulmonary exercise testing. |
||
Difficulties in activities of daily living |
||
| St. marianna university school of medicine |
| Ethics Committee of St. Marianna University School of Medicine | |
| 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511 Japan, Kanagawa, Kanagawa | |
+81-44-977-8111 |
|
| Approval | |
Mar. 21, 2024 |
No |
none |